Various in vitro experiments have examined the actions of royal jelly and its constituents on the immune system.
Experiments in animals have demonstrated immunoregulatory activities, with the administration of royal jelly (500 to 1,500 mg/kg body weight/day) increasing survival in tumor-bearing mice and demonstrating positive effects on bone marrow stem cells and tumor-induced splenic hematopoiesis.
Additionally, auto-immunity was inhibited in systemic lupus erythematous-prone mice, with a delay in disease progression, decreased proteinuria, and increased survival.
Increased healing rates were observed in guinea pig tympanic membrane perforation.
In an in vitro study using lymphocytes from healthy volunteers and patients with Graves disease, royal jelly caused lymphocytes to proliferate and certain cytokines to be secreted, suggesting a potential immunomodulatory role in the management of this disease.